Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax in Waldenström Macroglobulinemia
NCT04260217Phase 1Completed
- Sponsor
- Ascentage Pharma
- Start
- May 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of lisaftoclax in Waldenström macroglobulinemia (WM) (3 arms), sponsored by Ascentage Pharma. Primary endpoints: Dose Limiting Toxicity at 42 days and Maximally Tolerated Dose at 42 days. Started May 2021; status: completed.
02
Drugs
lisaftoclax
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04260217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260217.